Investor relations

We use innovative science to pursue novel treatments that address important medical challenges in neurological, autoimmune and rare diseases. Our therapies for multiple sclerosis and hemophilia are just the beginning.

Adam Koppel, Executive Vice President, Strategy and Business Development, to Return to Bain Capital

Biogen today announced that Adam Koppel, M.D., Ph.D., executive vice president, strategy and business development, will depart the company on June 2, 2016, to return to Bain Capital.

Events and webcasts

View our upcoming events and latest webcasts.

Stock information

Find Biogen’s current and historical stock information. 

NASDAQ: BIIB (Common Stock)

  • Volume
  • Today's Open $
  • Previous Close $
  • 52 Week High $
  • 52 Week Low $